Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay - Concepedia

Concepedia

Publication | Open Access

Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay

DOI Full Paper Access

99

Citations

18

References

2008

Year

Claire Bonfils, Ann Kalita, Marja Dubay, Lillian L. Siu, Michael A. Carducci, Gregory K. Reid, Robert E. Martell, Jeffrey M. Besterman, Zuomei Li

Clinical Cancer Research

Abstract

This study shows that MGCD0103 has sustained pharmacodynamic effects that can be monitored both in vitro and in vivo with a cell-based HDAC enzyme assay.

References

	Year	Citations
Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer William Kevin Kelly, Owen A. O’Connor, Lee M. Krug, Journal of Clinical Oncology	2005	898
Combined DNA Methyltransferase and Histone Deacetylase Inhibition in the Treatment of Myeloid Neoplasms Steven D. Gore, Stephen B. Baylin, Elizabeth A. Sugar, Cancer Research	2006	472
Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma Qin Ryan, Donna Headlee, Milin Acharya, Journal of Clinical Oncology	2005	406
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia John C. Byrd Blood	2004	401
Chapter 16 Resolution of Histonies by Polyacrylamide Gel Electrophoresis in Presence of Nonionic Detergents Alfred Zweidler Methods in cell biology Capillary ElectrophoresisBiochemistryBioanalysisPolyacrylamide Gel ElectrophoresisAnalytical Chemistry	1978	327
A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies Francis J. Giles, Thomas Fischer, Jörge E. Cortes, Clinical Cancer Research	2006	314
Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Jane A. Plumb, Paul W. Finn, Robert J. Williams, PubMed Histone ModificationsColon Tumor XenograftsChemoprevention StrategyHuman Tumor XenograftsTumor Biology	2003	313
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias Ivana Gojo, Anchalee Jiemjit, Jane B. Trepel, Blood	2006	282
Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies Xiaozhong Qian, William J. LaRochelle, Gulshan Ara, Molecular Cancer Therapeutics	2006	134
Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors Lillian L. Siu, Ignacio Durán, Wells A. Messersmith, Journal of Clinical Oncology	2008	118

Page 1